Abraham Scaria

Akebia Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index3.1kcitations84works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(29), Retinal Development and Disorders(25), Retinal Diseases and Treatments(18), RNA Interference and Gene Delivery(11), Retinal and Optic Conditions(11)

Publications84 total

AAV Gene Augmentation of Truncated Complement Factor H Differentially Rescues Ocular Complement Dysregulation in a Mouse Model
Investigative Ophthalmology & Visual Science·2023· 9 citedOpen Access
Addendum to: Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases
Nature Communications·2023Open Access
Data from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
2023Open Access
Supplementary Table 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
2023Open Access
Supplementary Table 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
2023Open Access
Supplementary Figure 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
2023Open Access
Supplementary Figure 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
2023Open Access
Data from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
2023Open Access
Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis
Molecular Therapy — Methods & Clinical Development·2022· 6 citedOpen Access
BEST Disease and Gene Therapy
International Ophthalmology Clinics·2021
Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases
Nature Communications·2021· 55 citedOpen Access
Preclinical evaluation of rAAV.CNGB1 in the Cngb1 knockout mouse model of retinitis pigmentosa.
2018
Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Gene Therapy·2018· 33 cited
Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes
Molecular Therapy — Methods & Clinical Development·2017· 140 citedOpen Access
Ocular gene therapy for neovascular AMD: a new era? – Authors' reply
The Lancet·2017· 1 cited
CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10
Investigative Ophthalmology & Visual Science·2017Open Access
3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Investigative Ophthalmology & Visual Science·2017· 3 citedOpen Access
Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial
The Lancet·2017· 220 cited
AAVS1-Targeted Plasmid Integration in AAV Producer Cell Lines
Human Gene Therapy Methods·2017· 8 cited
Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity
Stroke·2017· 27 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Samuel C. Wadsworth(15), Seng H. Cheng(14), Michael Lukason(13), William S.M. Wold(7), Peter Pecháň(7), Catherine R. O’Riordan(6), Jennifer A. Sullivan(6), Johanne Kaplan(6), Ann E. Tollefson(5), Richard J. Gregory(5), Elizabeth Barry(4), Susan Richards(3), Elizabeth DuFresne(3), Brenda Burnham(3), Shelley Nass(3), Maryellen Mattingly(3), Denise Woodcock(3), Hillard Rubin(3), William W. Hauswirth(3), Sam Wadsworth(3)